U.S. markets open in 8 hours 38 minutes

Qualigen Therapeutics, Inc. (QLGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.4800-0.0700 (-1.97%)
At close: 4:00PM EST
Full screen
Loading interactive chart...
  • Zacks Small Cap Research

    QLGN: Testing AS1411 as COVID-19 Treatment…

    By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update AS1411 Clinical Trial in COVID-19 to Initiate 1H21 On October 28, 2020, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced a positive pre-IND meeting with the U.S. FDA regarding the development of AS1411 as a treatment for COVID-19. AS1411 is a DNA aptamer that has exhibited antiviral activity in a number of

  • Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results
    PR Newswire

    Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results

    Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that Michael Poirier, President, Chief Executive Officer and Chairman, has issued a letter to Qualigen's stockholders. The full text is as follows:

  • Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials
    PR Newswire

    Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials

    Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has signed a contract with STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials. Preclinical studies at the University of Louisville's (UofL) Center for Infectious Disease have demonstrated the ability of AS1411, a novel aptamer-based molecule, to protect cells from the damaging effects of the novel coronavirus.